On this page
Typically prepared by a compounding pharmacy under the direction of a licensed healthcare professional — not an FDA-approved finished product in this form.
Overview
Product & regulatory status
FDA’s August 2026 notice states there are no FDA-approved indications for testosterone therapy in menopausal women.
Symptom-specific rationale
The trials evaluate androgen exposure for sexual-function outcomes; they do not establish a general hormone-optimization target. [1]
What the evidence shows
Postmenopausal HSDD trial
APHRODITE randomized 814 postmenopausal women with HSDD who were not taking estrogen. One testosterone-patch group improved satisfying sexual events versus placebo at 24 weeks. Safety follow-up was limited relative to lifelong cardiovascular and breast outcomes. [1]
Premenopausal results are narrower
A 16-week trial in 261 selected premenopausal women tested a testosterone spray. One treatment group had a modest improvement in sexual satisfaction; this does not establish benefit for all women reporting fatigue or low desire. [2]
What remains unknown
Benefits for cognition, general vitality and long-term disease prevention cannot be assumed from sexual-function trials. A testosterone result alone is not a comprehensive explanation of symptoms.
Safety
Androgenic adverse effects
The patch trial reported more androgenic effects, particularly unwanted hair growth. Long-term breast safety could not be resolved by the study. [1]
Compounded content
Testing of compounded testosterone products found substantial concentration variability. Those findings do not assess every pharmacy, but they matter when small exposure differences are clinically important. [4]
Approval gap
FDA’s 2026 workshop notice explicitly identifies the absence of approved menopausal testosterone indications and the need for clinically meaningful trial endpoints. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [5]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [6]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is female HRT one standardized testosterone product?
No. The term describes a clinical use, not a single formulation with one evidence base.
What should the treatment discussion define?
The distressing symptom, other possible causes, a measurable benefit target and an adverse-effect review plan.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Davis et al.: APHRODITE testosterone-patch trialNew England Journal of Medicine, 2008; 814 postmenopausal women with HSDD, not taking estrogen; efficacy to 24 weeks and safety to 52 weeks.
- Davis et al.: testosterone spray in premenopausal womenAnnals of Internal Medicine, 2008; 261 women, randomized placebo-controlled 16-week trial.
- FDA: testosterone use in menopausal women workshop noticeFederal Register, August 18, 2026; states no FDA-approved indications for testosterone therapy in menopausal women.
- Grober et al.: compounded testosterone contentJournal of Sexual Medicine, 2015; blinded testing of two batches from ten Toronto compounding pharmacies.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.